Why the study?
Do newer oral antiplatelet agents (prasugrel and ticagrelor) improve efficacy outcomes compared to clopidogrel in patients with acute coronary syndrome?
Population
Patients with acute coronary syndrome (ACS), including NSTE-ACS and STEMI, managed medically or with stents
Comparison
Oral antiplatelet therapies vs Clopidogrel
Design
Review
Authors
Loading...
Informs NP ACS prescribing per guidelines; leaves open prospective validation in real-world NP practice.
Do newer oral antiplatelet agents (prasugrel and ticagrelor) improve efficacy outcomes compared to clopidogrel in patients with acute coronary syndrome?
Current guidelines recommend ticagrelor over clopidogrel for maintenance therapy in ACS patients due to superior efficacy without increased severe bleeding risk.
Gesheff et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: